JP2017093436A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017093436A5 JP2017093436A5 JP2016232150A JP2016232150A JP2017093436A5 JP 2017093436 A5 JP2017093436 A5 JP 2017093436A5 JP 2016232150 A JP2016232150 A JP 2016232150A JP 2016232150 A JP2016232150 A JP 2016232150A JP 2017093436 A5 JP2017093436 A5 JP 2017093436A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- nucleic acid
- water
- lipid component
- ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 21
- 150000002632 lipids Chemical class 0.000 claims 15
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- -1 cationic lipid Chemical class 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 239000003960 organic solvent Substances 0.000 claims 4
- 229920000768 polyamine Polymers 0.000 claims 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 239000002502 liposome Substances 0.000 claims 3
- 230000007935 neutral effect Effects 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 125000002091 cationic group Chemical group 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims 2
- 229940063675 spermine Drugs 0.000 claims 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims 1
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 claims 1
- 239000005700 Putrescine Substances 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 229940063673 spermidine Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161443246P | 2011-02-15 | 2011-02-15 | |
| US61/443,246 | 2011-02-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553671A Division JP6054308B2 (ja) | 2011-02-15 | 2012-02-15 | 核酸を細胞へ送達する組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017093436A JP2017093436A (ja) | 2017-06-01 |
| JP2017093436A5 true JP2017093436A5 (https=) | 2017-09-14 |
| JP6313406B2 JP6313406B2 (ja) | 2018-04-18 |
Family
ID=46673165
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553671A Expired - Fee Related JP6054308B2 (ja) | 2011-02-15 | 2012-02-15 | 核酸を細胞へ送達する組成物及び方法 |
| JP2016232150A Active JP6313406B2 (ja) | 2011-02-15 | 2016-11-30 | 核酸を細胞へ送達する組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553671A Expired - Fee Related JP6054308B2 (ja) | 2011-02-15 | 2012-02-15 | 核酸を細胞へ送達する組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20140065204A1 (https=) |
| EP (1) | EP2675918B1 (https=) |
| JP (2) | JP6054308B2 (https=) |
| AU (1) | AU2012217685B2 (https=) |
| CA (1) | CA2827118A1 (https=) |
| WO (1) | WO2012112730A2 (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| ITRM20120480A1 (it) * | 2012-10-09 | 2014-04-10 | Uni Degli Studi Camerino | Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione. |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| PL4023249T3 (pl) | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| EP3626251A1 (en) | 2014-07-08 | 2020-03-25 | The Children's Medical Center Corporation | Compositions and methods for treating diabetes |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| WO2016191547A1 (en) | 2015-05-26 | 2016-12-01 | Comfort Care For Animals Llc | Liposome loading |
| JP7042739B2 (ja) | 2015-08-20 | 2022-03-28 | イプセン バイオファーム リミティド | 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法 |
| TW202400181A (zh) | 2015-08-21 | 2024-01-01 | 英商益普生生物製藥有限公司 | 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法 |
| JP6948313B6 (ja) | 2015-09-17 | 2022-01-14 | モデルナティエックス インコーポレイテッド | 治療剤の細胞内送達のための化合物および組成物 |
| EP3362563A1 (en) * | 2015-10-14 | 2018-08-22 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for liposomal formulation |
| EP4647126A3 (en) | 2015-10-16 | 2026-02-11 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
| PL3386484T3 (pl) | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| LT3394030T (lt) | 2015-12-22 | 2022-04-11 | Modernatx, Inc. | Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu |
| JP7132911B2 (ja) | 2016-09-16 | 2022-09-07 | バイオ－パス ホールディングス， インコーポレイテッド | リポソームアンチセンスオリゴヌクレオチドとの併用療法 |
| CN110402163A (zh) | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| EP4186888B1 (en) | 2017-03-15 | 2025-11-26 | ModernaTX, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
| CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| MA49023A (fr) * | 2017-03-29 | 2020-02-05 | Inst Basic Medical Sciences Cams | Application d'un composé ou d'un extrait de médecine chinoise traditionnelle dans la préparation d'un agent d'administration d'acide nucléique et produits apparentés correspondants |
| WO2019184991A1 (zh) * | 2018-03-29 | 2019-10-03 | 中国医学科学院基础医学研究所 | 化合物或中药提取物在制备核酸递送试剂中的应用及其相关产品 |
| IL269608B2 (en) | 2017-04-19 | 2024-06-01 | Bio Path Holdings Inc | Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease |
| EP3612160A4 (en) | 2017-04-19 | 2021-01-20 | Bio-Path Holdings, Inc. | P-ETHOXY NUCLEIC ACIDS FOR BCL2 INHIBITION |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| EP3675817A1 (en) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| JP6462073B1 (ja) * | 2017-09-04 | 2019-01-30 | 一丸ファルコス株式会社 | ｐＨ感受性リポソームの製造方法 |
| RS67724B1 (sr) * | 2017-10-20 | 2026-03-31 | BioNTech SE | Priprema i skladištenje lipozomskih rnk formulacija koje su pogodne za terapiju |
| EP3789043A4 (en) * | 2018-03-29 | 2022-08-03 | Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences | Extraction of plant source "medicinal soup" and manual preparation of "herbal medicine" and related products |
| WO2020061295A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| CA3113025A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| WO2020061457A1 (en) * | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| US11197827B2 (en) * | 2018-10-31 | 2021-12-14 | Microsoft Technology Licensing, Llc | Polynucleotide encapsulation and preservation using self-assembling membranes |
| WO2020200472A1 (en) * | 2019-04-05 | 2020-10-08 | Biontech Rna Pharmaceuticals Gmbh | Preparation and storage of liposomal rna formulations suitable for therapy |
| AU2020350759A1 (en) | 2019-09-19 | 2022-03-31 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| CA3155015A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents |
| WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| JP2023546359A (ja) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療 |
| AU2021401302A1 (en) | 2020-12-17 | 2023-07-06 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
| EP4262827A1 (en) | 2020-12-17 | 2023-10-25 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocytes |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| CA3215830A1 (en) | 2021-04-19 | 2022-10-27 | Rafael CUBAS | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| JP2024527961A (ja) | 2021-07-28 | 2024-07-26 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｋｒａｓ阻害剤と併用した腫瘍浸潤リンパ球療法によるがん患者の治療 |
| WO2023077015A2 (en) | 2021-10-27 | 2023-05-04 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| CA3237410A1 (en) | 2021-11-10 | 2023-05-19 | Friedrich Graf Finck VON FINCKENSTEIN | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| JP2025512401A (ja) | 2022-04-15 | 2025-04-17 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス |
| CN114984236B (zh) * | 2022-04-29 | 2023-03-24 | 深圳近邻生物科技有限公司 | 一种响应型核酸递送系统及其制备方法、交联聚合物载体 |
| WO2025108545A1 (en) * | 2023-11-22 | 2025-05-30 | Danmarks Tekniske Universitet | Delivery of nucleotides from injectable biomaterial |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5908635A (en) * | 1994-08-05 | 1999-06-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the liposomal delivery of nucleic acids |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
| US6794128B2 (en) | 1998-04-24 | 2004-09-21 | The Regents Of The University Of California | Methods of selecting internalizing antibodies |
| US7780882B2 (en) * | 1999-02-22 | 2010-08-24 | Georgetown University | Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent |
| ATE470435T1 (de) * | 2003-11-03 | 2010-06-15 | Yissum Res Dev Co | Verfahren zur auswahl von kationischen oder anionischen liposomen zur behandlung einer schleimhautmembran und diese enthaltendes set |
| JP4651276B2 (ja) * | 2003-11-12 | 2011-03-16 | テルモ株式会社 | リポソームを体内より排泄する抗体およびリポソームの血中クリアランス促進剤 |
| JP3941808B2 (ja) | 2004-10-28 | 2007-07-04 | 株式会社日立製作所 | 動画像の変化点検出方法及び装置 |
| US20070171077A1 (en) | 2006-01-26 | 2007-07-26 | Behrouz Kawarizadeh | License Plate Incorporating RFID Device |
| DE602008006684D1 (de) | 2007-02-09 | 2011-06-16 | Nat Univ Corp Nara Inst | C70 fulleren-enthaltendes liposom, verfahren zu seiner herstellung und seine verwendung |
| KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| AU2008309880B2 (en) | 2007-10-12 | 2014-07-10 | Biontech Delivery Technologies Gmbh | Amphoteric liposomes comprising neutral lipids |
| AU2008325122A1 (en) * | 2007-11-09 | 2009-05-14 | Northeastern University | Self-assembling micelle-like nanoparticles for systemic gene delivery |
| JP2012505913A (ja) * | 2008-10-16 | 2012-03-08 | マリーナ バイオテック，インコーポレイテッド | 遺伝子発現を抑制する治療におけるリポソームによる効率的な送達のプロセスおよび組成物 |
| JP5532635B2 (ja) * | 2009-03-11 | 2014-06-25 | 凸版印刷株式会社 | 核酸含有リポソームを用いた遺伝子解析方法及び遺伝子解析キット |
| WO2010125544A1 (en) | 2009-04-30 | 2010-11-04 | Genetic Immunity Kft. | Immunogenic nanomedicine composition and preparation and uses thereof |
| US8420118B2 (en) * | 2009-09-10 | 2013-04-16 | The Board Of Regents Of The University Of Oklahoma | Anionic lipids and lipid nano-structures and methods of producing and using same |
-
2012
- 2012-02-15 WO PCT/US2012/025324 patent/WO2012112730A2/en not_active Ceased
- 2012-02-15 EP EP12746634.0A patent/EP2675918B1/en not_active Not-in-force
- 2012-02-15 JP JP2013553671A patent/JP6054308B2/ja not_active Expired - Fee Related
- 2012-02-15 CA CA2827118A patent/CA2827118A1/en not_active Abandoned
- 2012-02-15 AU AU2012217685A patent/AU2012217685B2/en not_active Ceased
-
2013
- 2013-08-15 US US13/967,664 patent/US20140065204A1/en not_active Abandoned
-
2016
- 2016-01-22 US US15/004,481 patent/US10087464B2/en not_active Expired - Fee Related
- 2016-11-30 JP JP2016232150A patent/JP6313406B2/ja active Active
-
2018
- 2018-07-02 US US16/025,503 patent/US20190017073A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017093436A5 (https=) | ||
| JP7496808B2 (ja) | リポカチオン性デンドリマーおよびその使用 | |
| JP7480220B2 (ja) | カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質 | |
| Malhotra et al. | Glycine-terminated dendritic amphiphiles for nonviral gene delivery | |
| AU2016385135B2 (en) | Bifurcating mixers and methods of their use and manufacture | |
| Thomas et al. | Polyamine–DNA interactions and development of gene delivery vehicles | |
| JP6313406B2 (ja) | 核酸を細胞へ送達する組成物及び方法 | |
| CN105939699B (zh) | 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途 | |
| JP2012526858A5 (https=) | ||
| JP2010184947A5 (https=) | ||
| JP2019508371A5 (https=) | ||
| CN105916839B (zh) | 阳离子性脂质 | |
| JP2009513151A5 (https=) | ||
| CA2748520A1 (en) | Pharmaceutical composition containing an anionic drug, and a production method therefor | |
| CN107028886A (zh) | 含有核酸的脂质粒子及相关的方法 | |
| CN108366964A (zh) | 制备含阴离子药物的聚合物胶束的方法 | |
| JP2012532839A5 (https=) | ||
| WO2010142660A2 (en) | Drug delivery system | |
| CN101646443B (zh) | 速效型核酸转运用载体组合物 | |
| Kocsis et al. | Supramolecular rulers enabling selective detection of pure short ssDNA via chiral self-assembly | |
| US20250319035A1 (en) | Cationic lipid nanoparticle having high transfection efficiency and preparation method therefor | |
| WO2025011380A1 (zh) | 脂质化合物、组合物及其制备方法和应用 | |
| JP2024541897A5 (https=) | ||
| JP5808246B2 (ja) | 核酸複合体、及び核酸送達用組成物 | |
| CN119913209A (zh) | 一种用于向细胞内递送核酸的组合物 |